<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-144566</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">New perspectives in the approach to age-related macular degeneration</dc:title>
<dc:description xml:lang="en">The approval of aflibercept for the neovascular form of age-related macular degeneration has opened up the possibility of treating patients with fewer injections, since the drug can be administered once every two months. Aflibercept can also be used as rescue therapy in patients with suboptimal response to other antiangiogenic treatments. The present study reviews the scientific evidence on aflibercept, both in treatment-naïve patients and in those with an unsatisfactory response to conventional treatments (AU)</dc:description>
<dc:creator>Zapata, MA</dc:creator>
<dc:creator>Gallego-Pinazo, R</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La aprobación de aflibercept para el tratamiento de la forma neovascular de degeneración macular asociada a la edad ha abierto la posibilidad de tratar a los pacientes con menos inyecciones dada la bimestralidad de dosificación de aflibercept, así como rescatar pacientes con respuesta subóptima a otros tratamientos antiangiogénicos. El presente manuscrito revisa la evidencia científica existente respecto al tratamiento con aflibercept, tanto en pacientes no tratados previamente como en aquellos con respuesta insatisfactoria a los tratamientos convencionales (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;90(supl.1): 11-14, mar. 2015.</dc:source>
<dc:identifier>ibc-144566</dc:identifier>
<dc:title xml:lang="es">Nuevas perspectivas en el abordaje de la degeneración macular asociada a la edad</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d10791^s22048</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d51811^s22002</dc:subject>
<dc:subject>^d8440^s22053</dc:subject>
<dc:subject>^d51811^s22054</dc:subject>
<dc:subject>^d14190^s22066</dc:subject>
<dc:subject>^d14190^s22045</dc:subject>
<dc:subject>^d10791^s22066</dc:subject>
<dc:subject>^d8440^s22044</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d33766^s22044</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d8440^s22013</dc:subject>
<dc:subject>^d10791^s22045</dc:subject>
<dc:subject>^d33766^s22053</dc:subject>
<dc:subject>^d8440^s22012</dc:subject>
<dc:subject>^d10791^s37748</dc:subject>
<dc:type>article</dc:type>
<dc:date>201503</dc:date>
</metadata>
</record>
</ibecs-document>
